Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T19:34:33.908Z Has data issue: false hasContentIssue false

Cognitive Agents

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 446 - 475
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Garnock-Jones, K. P. (2011). Dextromethorphan/quinidine: in pseudobulbar affect. CNS Drugs, 25, 435–445.CrossRefGoogle ScholarPubMed
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescribers Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Avanir Pharmaceuticals Inc. (2019). Nudexta Package Insert. Aliso Viejo, California.Google Scholar
Pioro, E. P., Brooks, B. R., Cummings, J., et al. (2010). Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol, 68, 693–702.CrossRefGoogle ScholarPubMed

References

Birks, J. S., Harvey, R. (2003). Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev, CD001190, doi: 10.1002/14651858CrossRefGoogle Scholar
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescribers Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Camber Pharmaceuticals Inc. (2020). Donepezil Package Insert. Piscataway, New Jersey.Google Scholar
Jones, R. W. (2003). Have cholinergic therapies reached their clinical boundary in Alzheimer’s disease? Int J Geriatr Psychiatry, 18, S7–S13.CrossRefGoogle ScholarPubMed
Bentue-Ferrer, D., Tribut, O., Polard, E., et al. (2003). Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs, 17, 947–963.CrossRefGoogle ScholarPubMed

References

Olin, J., Schneider, L. (2002). Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev, CD001747, doi: 10.1002/14651858CrossRefGoogle Scholar
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescribers Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Stahl, S. M. (2000). The new cholinesterase inhibitors for Alzheimer’s disease, part 2: illustrating their mechanisms of action. J Clin Psychiatry, 61, 813–814.CrossRefGoogle ScholarPubMed
Stahl, S. M. (2000). The new cholinesterase inhibitors for Alzheimer’s disease, part 1: their similarities are different. J Clin Psychiatry, 61, 710–711.CrossRefGoogle ScholarPubMed
Coyle, J., Kershaw, P. (2001). Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease. Biol Psychiatry, 49, 289–299.CrossRefGoogle ScholarPubMed
Bonner, L. T., Peskind, E. R. (2002). Pharmacologic treatments of dementia. Med Clin North Am, 86, 657–674.CrossRefGoogle ScholarPubMed
Jones, R. W. (2003). Have cholinergic therapies reached their clinical boundary in Alzheimer’s disease? Int J Geriatr Psychiatry, 18, S7–S13.CrossRefGoogle ScholarPubMed
Zydus Pharmaceuticals USA Inc. (2020). Galantamine Package Insert. Pennington, New Jersey.Google Scholar
Bentue-Ferrer, D., Tribut, O., Polard, E., et al. (2003). Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs, 17, 947–963.CrossRefGoogle ScholarPubMed

References

Areosa, S. A., Sherriff, F. (2003). Memantine for dementia. Cochrane Database Syst Rev, CD003154, doi: 10.1002/14651858CrossRefGoogle Scholar
Sani, G., Serra, G., Kotzalidis, G. D., et al. (2012). The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs, 26, 663–690.CrossRefGoogle Scholar
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescribers Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Tariot, P. N., Federoff, H. J. (2003). Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord, 17 Suppl. 4, S105–113.CrossRefGoogle ScholarPubMed
Strides Pharma Inc. (2020). Memantine Package Insert. East Brunswick, New Jersey.Google Scholar

References

Birks, J., Grimley Evans, J., Iakovidou, V., et al. (2009). Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev, CD001191, doi: 10.100214651858CrossRefGoogle Scholar
Dhillon, S. (2011). Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer’s type. Drugs, 71, 1209–1231.CrossRefGoogle ScholarPubMed
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescribers Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Nivagen Pharmaceuticals Inc. (2020). Rivastigmine Package Insert. Sacramento, California.Google Scholar
Jones, R. W. (2003). Have cholinergic therapies reached their clinical boundary in Alzheimer’s disease? Int J Geriatr Psychiatry, 18, S7–S13.CrossRefGoogle ScholarPubMed
Bentue-Ferrer, D., Tribut, O., Polard, E., et al. (2003). Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs, 17, 947–963.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Cognitive Agents
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Cognitive Agents
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Cognitive Agents
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×